NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

PRQR

ProQR Therapeutics N.V

Apr 17 • 04:00PM ET

1.14

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • Netherlands • NASD

Peers: ALNY SRPT BMRN IONS ARWR QURE BBIO RGNX BLUE ADVM

| Held by: QQQS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.35	Insider Own	32.74%	Shs Outstand	102.71M	Perf Week	0.88%
Market Cap	119.94M	Forward P/E	-	EPS next Y	-0.50	Insider Trans	0.00%	Shs Float	70.76M	Perf Month	-30.06%
Income	-30.04M	PEG	-	EPS next Q	-0.10	Inst Own	42.77%	Short Float	1.19%	Perf Quarter	-50.43%
Sales	20.43M	P/S	5.87	EPS this Y	-18.55%	Inst Trans	31.14%	Short Ratio	1.67	Perf Half Y	-37.02%
Book/sh	0.89	P/B	1.28	EPS next Y	-15.33%	ROA	-18.42%	Short Interest	0.84M	Perf Year	-43.00%
Cash/sh	1.47	P/C	0.78	EPS next 5Y	-15.79%	ROE	-43.72%	52W Range	1.07 - 4.62	Perf YTD	-56.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	25.70%	ROI	-29.12%	52W High	-75.32%	Beta	0.46
Dividend TTM	-	Quick Ratio	3.95	Sales past 5Y	82.57%	Gross Margin	85.38%	52W Low	6.54%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	3.95	EPS Y/Y TTM	7.54%	Oper. Margin	-164.73%	RSI (14)	28.26	Volatility	9.52% 9.15%
Employees	-	Debt/Eq	0.18	Sales Y/Y TTM	190.40%	Profit Margin	-147.03%	Recom	1.00	Target Price	10.68
Option/Short	Yes / Yes	LT Debt/Eq	0.12	EPS Q/Q	-36.70%	Payout	-	Rel Volume	0.92	Prev Close	1.14
Sales Surprise	-11.08%	EPS Surprise	-3.30%	Sales Q/Q	30.09%	Earnings	Mar 13 BMO	Avg Volume	504.43K	Price	1.14
SMA20	-12.64%	SMA50	-36.57%	SMA200	-50.96%	Trades		Volume	464,845	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-10-25	Upgrade	Citigroup	Neutral → Buy	$4
Jan-10-25	Initiated	Oppenheimer	Outperform	$15
Oct-29-24	Upgrade	Raymond James	Outperform → Strong Buy	$6 → $14
Nov-08-23	Upgrade	Chardan Capital Markets	Neutral → Buy	$2
Mar-30-23	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$1.50 → $5
Dec-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$0.80 → $5
Feb-14-22	Downgrade	Citigroup	Buy → Neutral	$37 → $1.70
Feb-11-22	Downgrade	Stifel	Buy → Hold	$20 → $3
Feb-11-22	Downgrade	Raymond James	Strong Buy → Mkt Perform
Feb-01-22	Initiated	Raymond James	Strong Buy	$19
May-03-21	Initiated	Stifel	Buy	$20
Mar-25-21	Reiterated	Citigroup	Buy	$33 → $44
Nov-03-20	Resumed	Cantor Fitzgerald	Overweight	$22
Mar-12-19	Reiterated	Chardan Capital Markets	Buy	$21 → $25
Dec-19-18	Initiated	RBC Capital Mkts	Outperform
Nov-15-18	Initiated	Citigroup	Buy	$32
Sep-19-18	Initiated	Evercore ISI	Outperform
Sep-26-17	Reiterated	JMP Securities	Mkt Outperform	$14 → $20
Jun-20-16	Initiated	Chardan Capital Markets	Neutral	$4.50
Oct-15-14	Initiated	Deutsche Bank	Buy	$32

Show Previous Ratings

Apr-15-25 09:01AM	Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength? (Zacks)
Apr-14-25 07:00AM	ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth (GlobeNewswire) +5.36%
Mar-13-25 07:00AM	ProQR Announces Year End 2024 Operating and Financial Results (GlobeNewswire) -5.95%
Dec-12-24 07:16AM	ProQR Therapeutics announces $8.1M in new funding from RSRT (TipRanks)
Dec-11-24 07:00AM	ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration (GlobeNewswire)
08:00AM	Loading…
Dec-10-24 08:00AM	ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist (GlobeNewswire)
Dec-06-24 06:47AM	ProQR Therapeutics price target raised to $8 from $5 at JMP Securities (TipRanks)
Dec-05-24 08:00AM	ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 (GlobeNewswire)
Nov-08-24 07:26AM	ProQR Therapeutics sees cash runway into mid-2027 (TipRanks) +5.60%
Nov-07-24 07:00AM	ProQR Announces Third Quarter 2024 Operating and Financial Results (GlobeNewswire)
Oct-25-24 04:45PM	ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement (GlobeNewswire)
Oct-22-24 10:15PM	ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement (GlobeNewswire) -6.67% -7.67%
04:01PM	ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares (GlobeNewswire)
Oct-07-24 08:00AM	ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society (GlobeNewswire)
Sep-10-24 04:30PM	ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
07:00AM	Loading…
Aug-08-24 07:00AM	ProQR Announces Second Quarter 2024 Operating and Financial Results (GlobeNewswire) +12.30%
Jun-18-24 08:00AM	ProQR Announces Presentation on its Axiomer RNA Editing Technology at RNA Editing Summit (GlobeNewswire)
May-09-24 07:00AM	ProQR Announces First Quarter 2024 Operating and Financial Results (GlobeNewswire)
May-08-24 08:00AM	ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer RNA Editing Program Targeting NTCP for Cholestatic Diseases (GlobeNewswire)
Apr-23-24 07:00AM	ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024 (GlobeNewswire)
Apr-22-24 04:31PM	ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting (GlobeNewswire)
Apr-19-24 07:00AM	ProQR Achieves Successful Defense of New Challenge to its Axiomer IP Portfolio (GlobeNewswire) +6.99%
Mar-13-24 07:00AM	ProQR Announces Year End 2023 Operating and Financial Results (GlobeNewswire) +13.66%
Feb-15-24 07:00AM	ProQR Announces Japanese Axiomer Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing (GlobeNewswire)
Jan-19-24 07:00AM	ProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024 (GlobeNewswire)
Jan-05-24 07:00AM	ProQR and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration (GlobeNewswire)
Dec-28-23 08:44AM	Is ProQR (PRQR) Stock a Solid Choice Right Now? (Zacks)
Dec-08-23 07:30AM	ProQR Therapeutics Announces Transaction Completed for Th a to Acquire Sepofarsen and Ultevursen Ophthalmic Assets (GlobeNewswire)
Nov-07-23 07:00AM	ProQR Announces Third Quarter 2023 Operating and Financial Results (GlobeNewswire) +10.66%
Nov-06-23 07:00AM	ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing (GlobeNewswire)
08:00AM	Loading…
Sep-28-23 08:00AM	ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-27-23 07:00AM	ProQR Therapeutics Provides Update on Ophthalmic Assets (GlobeNewswire)
Sep-07-23 08:00AM	ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-08-23 06:37AM	ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are retail investors with 50% stake, while 31% is held by institutions (Simply Wall St.)
Aug-03-23 07:00AM	ProQR Announces Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Aug-01-23 07:00AM	ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQRs Sepofarsen and Ultevursen Ophthalmic Assets (GlobeNewswire) +7.33%
Jul-06-23 07:00AM	ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit (GlobeNewswire)
Jun-28-23 06:02AM	ProQR Therapeutics' (NASDAQ:PRQR) investors will be pleased with their impressive 109% return over the last year (Simply Wall St.)
May-18-23 07:02AM	ProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From Profitability (Simply Wall St.)
May-16-23 07:00AM	ProQR Announces First Quarter 2023 Operating and Financial Results (GlobeNewswire) -7.29%
May-09-23 08:00AM	ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 (GlobeNewswire)
Apr-20-23 08:00AM	ProQR Announces Upcoming Investor Conferences in April and May (GlobeNewswire)
Apr-18-23 08:00AM	ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023 (GlobeNewswire) -6.47%
Mar-29-23 12:30PM	Why Shares of ProQR Therapeutics Dropped on Wednesday (Motley Fool) -29.61%
08:00AM	ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event (GlobeNewswire)
Mar-14-23 08:00AM	ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing (GlobeNewswire) +7.85%
Mar-07-23 08:00AM	ProQR to Present at Upcoming Scientific and Industry Conferences (GlobeNewswire)
Feb-28-23 08:00AM	ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 (GlobeNewswire)
Feb-01-23 05:11AM	Individual investors account for 45% of ProQR Therapeutics N.V.'s (NASDAQ:PRQR) ownership, while institutions account for 35% (Simply Wall St.)
Dec-29-22 11:36AM	Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More (Zacks) +10.13%
Dec-23-22 12:14PM	ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly (Zacks)
Dec-22-22 09:12AM	ProQR's stock jumps on expanded RNA deal with Lilly (MarketWatch) +63.64%
08:53AM	ProQR Therapeutics Shares Soar As Eli Lilly Expands RNA Collaboration (Benzinga)
06:15AM	ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform (GlobeNewswire)
06:00AM	Lilly and ProQR to Expand RNA Editing Collaboration (PR Newswire)
05:28AM	ProQR Therapeutics (NASDAQ:PRQR) shareholders have endured a 83% loss from investing in the stock three years ago (Simply Wall St.)
Nov-14-22 04:30PM	ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 (GlobeNewswire) +5.18%
Nov-11-22 05:54AM	ProQR Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Nov-09-22 08:25AM	ProQR (PRQR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	ProQR Announces Third Quarter 2022 Operating and Financial Results (GlobeNewswire)
Nov-03-22 07:00AM	ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference (GlobeNewswire)
Aug-12-22 02:05PM	Raymond James Bullish On This Penny Stock's Reprioritized Pipeline (Benzinga) +5.51%
Aug-11-22 02:48PM	This Penny Stock Biotech Offloads Eye Portfolio To Focus On RNA-Editing (Benzinga)
07:00AM	ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs (GlobeNewswire)
Aug-04-22 10:25AM	ProQR (PRQR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	ProQR Announces Second Quarter 2022 Operating and Financial Results (GlobeNewswire)
Jul-08-22 07:06AM	Investors in ProQR Therapeutics (NASDAQ:PRQR) have unfortunately lost 90% over the last three years (Simply Wall St.)
Jun-28-22 07:00AM	ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium (GlobeNewswire)
Jun-01-22 07:00AM	ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates (GlobeNewswire) +11.97%
May-09-22 07:00AM	ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022 (GlobeNewswire) -8.97%
May-05-22 08:15PM	ProQR (PRQR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:30PM	ProQR Announces First Quarter 2022 Operating and Financial Results (GlobeNewswire)
May-03-22 09:55AM	Bears are Losing Control Over ProQR (PRQR), Here's Why It's a 'Buy' Now (Zacks)
Apr-28-22 03:02PM	ProQR (PRQR) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-26-22 04:10PM	ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022 (GlobeNewswire) -5.76%
Apr-19-22 04:30PM	ProQR to Participate in the Kempen Life Sciences Conference (GlobeNewswire)
Apr-13-22 09:49AM	ProQR Therapeutics Pulls Plug On Inherited Retinal Disease Programs, Cuts 30% Workforce (Benzinga) -12.64%
07:00AM	ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy (GlobeNewswire)
Apr-12-22 04:30PM	Lennar Corporation Declares Quarterly Dividends (PR Newswire)
Apr-04-22 07:00AM	ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit (GlobeNewswire) +8.89%
Mar-23-22 04:30PM	ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit (GlobeNewswire)
Mar-07-22 07:00AM	ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board (GlobeNewswire)
Feb-24-22 08:35AM	ProQR (PRQR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results (GlobeNewswire)
Feb-17-22 03:02PM	Will ProQR (PRQR) Report Negative Q4 Earnings? What You Should Know (Zacks)
Feb-14-22 06:23PM	Why ProQR Therapeutics Stock Got Slammed Again Monday (Motley Fool) -10.07%
04:38PM	ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III Study (Zacks)
Feb-11-22 01:24PM	Why ProQR Therapeutics Is Crashing Today (Motley Fool) -75.35%
07:00AM	ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10 (GlobeNewswire)
Feb-10-22 07:19PM	Raymond James 2 Stock Picks With Over 70% Upside Potential (TipRanks)
Feb-07-22 04:30PM	ProQR to Present at Upcoming SVB Leerink Conference (GlobeNewswire) +9.59%
Feb-02-22 02:11AM	Strength Seen in ProQR (PRQR): Can Its 7% Jump Turn into More Strength? (Zacks) -5.66%
Jan-04-22 07:00AM	ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen (GlobeNewswire)
Dec-30-21 07:00AM	ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital (GlobeNewswire)
Dec-16-21 07:00AM	ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa (GlobeNewswire)
Nov-18-21 04:01PM	ProQR Announces Highlights from Analyst Event (GlobeNewswire)
Nov-11-21 07:00AM	ProQR to Webcast Virtual Analyst Event on November 18 (GlobeNewswire)
Nov-08-21 04:30PM	ProQR Announces Upcoming Investor Conferences in November and December (GlobeNewswire)
Nov-04-21 10:05AM	ProQR (PRQR) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.62%
07:00AM	ProQR Announces Third Quarter 2021 Operating and Financial Results (GlobeNewswire)

ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRQR

ProQR Therapeutics N.V

Upgrade your FINVIZ experience